Franco Felizarta, MD
Enriched profilePhysician, Infectious Disease (private practice) · Private practice
Franco Felizarta is Physician, Infectious Disease (private practice) at Private practice. OpenAlex indexes 60 publications with 4,012 citations (h-index 23); ClinicalTrials.gov lists 3 registered studies with this person as an investigator.
Data verified 11 Oct 2026
Overview
Updated 14 Oct 2026
Franco Felizarta, MD, is Physician, Infectious Disease (private practice). The public record shows 60 publications with 4,012 citations (h-index 23), centered on Hepatitis C virus research, HIV/AIDS drug development and treatment, Animal Virus Infections Studies. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 15 companies.
- Most recent indexed publication: 2026 · Open forum infectious diseases
- Top research focus: Hepatitis C virus research
- 3 registered trials on ClinicalTrials.gov
- Open Payments reporting from 15 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 3 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 38.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:
- Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects
Sponsor: Felizarta, Franco, M.D.
Industry payments
Updated 14 Oct 2026
15 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year202540 payments$24,075openpaymentsdata.cms.gov ↗
- ViiV Healthcare CompanyProgram year202544 payments$19,637openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year202515 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
87.9%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor22.6%Juluca35%Isentress Hd20%Tivicay18%Dovato18%Isentress5%Cabenuva4%Part D<11 patientsProtease Inhibitor11.3%Prezcobix65%Symtuza19%Darunavir12%Ritonavir5%Part D<11 patients+ 19 more classes in this area
Genitourinary & hormones
4.5%Estrogen4.5%Estradiol100%Part D≥34 patientsBlood & clotting
3.4%Salt solutions3.4%Sodium Chloride100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b study.
Nature medicine
Clinical Trial2025 - Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With HIV-1: A Substudy of the Phase 3b ATLAS-2M Study.
Clinical infectious diseases
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01
- 02Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 InfectionArticle439 citations2018
- 03
- 04
- 05Brief ReportArticle227 citations2015
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
University of the Philippines College of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →reviews.rater8.com ↗ - Board certified
American Board of Internal Medicine: Internal Medicine and Infectious Disease
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →reviews.rater8.com ↗
Editorial & leadership roles
journal and society appointments- HIV Specialist
American Academy of HIV Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →reviews.rater8.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Yousef Khader
Jordan University of Science and Technology
Thomas Walsh, MD
Cornell University
Vance Fowler, MD
Duke University
Derrick W. Crook
Nuffield Orthopaedic Centre